Search company, investor...
ConcertAI company logo

ConcertAI

concertai.com

Founded Year

2017

Stage

Series C | Alive

Total Raised

$320M

Valuation

$0000 

Last Raised

$150M | 10 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About ConcertAI

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

Headquarters Location

501 Boylston Street Floor 10

Boston, Massachusetts, 02116,

United States

Missing: ConcertAI's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing ConcertAI

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

These vendors sell access to their aggregated deidentified datasets, which is used for building, training, and testing AI/ML algorithms, or as the basis for synthetic datasets.

ConcertAI named as Leader among 14 other companies, including Tempus, Aetion, and Truveta.

Missing: ConcertAI's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ConcertAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ConcertAI is included in 12 Expert Collections, including Digital Health.

D

Digital Health

21,907 items

Startups recreating how healthcare is delivered

U

Unicorns- Billion Dollar Startups

1,204 items

C

Clinical Trials Tech

366 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

A

AI 100

100 items

The winners of the 4th annual CB Insights AI 100.

C

Conference Exhibitors

5,302 items

ConcertAI Patents

ConcertAI has filed 1 patent.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Classification algorithms
  • Machine learning
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/29/2021

Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification

Application

Application Date

10/29/2021

Grant Date

Title

Related Topics

Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification

Status

Application

Latest ConcertAI News

Former Pfizer exec Melissa Gunn wants to use data to transform the pharma industry as she joins Constellation

Jan 13, 2023

Gunn, the former head of global oncology strategy at Pfizer and SVP of customer success at ConcertAI, will lead the company’s pharmaceutical division in the new role. The end of 2022 and start of 2023 has been something of a carousel with pharma executives and marketing agency heads  joining ,  leaving ,  moving ,  promoting  and so on. To that end,  Constellation , a software-as-a-service platform that assists brands and companies launch and manage hyper-targeted campaigns at scale, has hired Melissa Gunn as VP of customer success and strategic partnerships. Gunn, the former head of global oncology strategy at Pfizer and SVP of customer success at ConcertAI, will lead the company’s pharmaceutical division in the new role. In a conversation with PRWeek's sister brand MM+M, Gunn said what most excited her about the position was being about to use data and technology to transform the pharma industry. Whereas her work at Pfizer and ConcertAI primarily focused on using data to innovate the drug development and clinical trial processes, Gunn said she views Constellation’s work as affecting how medical marketing is carried out. Constellation is aiming to offer technology to pharma brands and their marketing counterparts that will enable the speed and scale necessary to compete in what is still a highly regulated market, she added. Relying on the lessons learned from both of her previous leadership stints is also influencing Gunn’s approach to the role. “When I was at Pfizer, I ran both sales and marketing for the hematology portfolio, so I’ve been on the front lines meeting with doctors. I understand what marketers are looking for, what they’re measuring internally and how to get there,” she said. “But I also have a legal background and I used to be the person reviewing every single piece that came through. I’ve learned from all different aspects what it takes to get these campaigns through and also what the advantages are, in my view, related to both speed, scale and personalization in a much different way than there has been historically.” Constellation CEO Diana Lee said Gunn’s background at a Fortune 100 company like Pfizer and then her move to a startup like ConcertAI made it a no-brainer to bring her onboard. The company has already signed contracts with 11 companies, including their first client Biohaven Pharmaceuticals, which is ironically  now part of Pfizer . Looking ahead, Lee said she’s looking forward to working with pharma brands and medical marketing agencies to harness the possibilities in the digital realm for creative content. “This area needs to be disrupted and I know that [Gunn] is the right person to actually do it,” she said. “Overall, we’re eager because now that we have funding and are moving forward into the future, we will be able to do great things together and disrupt marketing for the pharmaceutical industry.”

ConcertAI Frequently Asked Questions (FAQ)

  • When was ConcertAI founded?

    ConcertAI was founded in 2017.

  • Where is ConcertAI's headquarters?

    ConcertAI's headquarters is located at 501 Boylston Street, Boston.

  • What is ConcertAI's latest funding round?

    ConcertAI's latest funding round is Series C.

  • How much did ConcertAI raise?

    ConcertAI raised a total of $320M.

  • Who are the investors of ConcertAI?

    Investors of ConcertAI include Sixth Street Partners, AllianceBernstein, Maverick Ventures Israel, Declaration Partners, SymphonyAI Group and 3 more.

  • Who are ConcertAI's competitors?

    Competitors of ConcertAI include Holmusk, Clearsense, Validic, nference, Komodo Health, COTA, Tempus, PicnicHealth, Owkin, OncoHealth and 39 more.

Compare ConcertAI to Competitors

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology. The company was founded in 2016 and is based in New York, New York.

Datavant Logo
Datavant

Datavant is dedicated to accelerating the discovery, development, and commercialization of new medicines through machine learning. It aims to partner with biomedical research institutions to eliminate silos of information and unlock insights from healthcare data. The firm was founded in 2017 and is based in San Francisco, California.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine-learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. The company was founded in 2015 and is based in Chicago, Illinois.

nference Logo
nference

nference makes biomedical knowledge computable to solve urgent healthcare problems of biopharmas and medical centers. The company offers EMR data, software products and services, record de-identification, curation of unstructured information, and data creation via digitization of pathology and molecular sequencing. It was founded in 2013 and is based in Cambridge, Massachusetts.

Mendel.ai Logo
Mendel.ai

Mendel.ai is the artificial intelligence engine and technology powering Mendel Health. Mendel Health is a for-profit corporation that uses deep learning technology to sift through unstructured data in medical literature and patient health records in order to suggest evidence-based treatment options and to continuously update the results whenever a new matching trial or treatment emerges. The company is currently focused on oncology and cancer patient populations. Mendel was founded in 2016 and is based in San Jose, California.

Aetion Logo
Aetion

Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.